Table 7 Cost input included in the analysis
Type | Description | Value | Source |
|---|---|---|---|
Treatment acquisition | Acquisition cost – Brolucizumab (€/vial)a | €680.00a | |
Acquisition cost – Aflibercept (€/vial)a | €740.00a | ||
Number of injections, Year 1 – Brolucizumab (N/year) | 6.66 | ||
Number of injections, Year 1 – Aflibercept (N/year) | 7.23 | ||
Number of injections, Year 2 – Brolucizumab (N/year) | 4.84 | ||
Number of injections, Year 2 – Aflibercept (N/year) | 5.58 | ||
Number of injections, Subsequent years – Brolucizumab (N/year) | 4.84 | ||
Number of injections, Subsequent years – Aflibercept (N/year) | 5.58 | ||
Treatment administration | Administration cost of anti-VEGF drug (€/administration) | €247.20 | Elaboration from [25] |
Disease monitoring | Unit cost - Optical Coherence Tomography (€) | €36.07 | Elaboration from [25] |
Resource use - Optical Coherence Tomography (N/anno) | 1.00 | ||
TREA management | Unit cost (€) - Cataract | €994.00 | DH 039 [27] |
Unit cost (€) - Endophthalmitis | €1522.00 | DH 042 [27] | |
Unit cost (€) - Intraocular inflammation | €20.66 | Tariff Code 89.7 [28] | |
Unit cost (€) - Detachment of the retina | €1491.00 | DH 036 [27] | |
Unit cost (€) - Retinal pigment epithelial tear | €1491.00 | ||
Unit cost (€) - Retinal tear | €1491.00 | ||
Vision loss | Total costs direct of blindness (€) | €7856 | [26] |
Total costs direct of low vision (€) | €1964 | ||
Total costs (direct and indirect) of blindness (€) | €17,897 | ||
Total costs (direct and indirect) of low vision (€) | €4474 |